OncoBeta's Breakthrough 12-Month Findings for Skin Cancer Therapy

OncoBeta's Transformative Findings from Recent Clinical Study

OncoBeta GmbH has made remarkable strides in the treatment of non-melanoma skin cancer (NMSC) with its innovative epidermal radioisotope therapy, Rhenium-SCT. Recent 12-month results from an international Phase IV clinical trial have showcased the efficacy and safety of this cutting-edge therapy, painting a promising picture for patients battling this common cancer type.

Understanding the EPIC-Skin Study

The EPIC-Skin Study, which stands for Efficacy of Personalised Irradiation with Rhenium-SCT for the Treatment of Non-Melanoma Skin Cancer, was meticulously designed to evaluate the treatment's effectiveness, safety, and patient-reported outcomes. Not only does it focus on the clinical results, but it also takes into account the quality of life, treatment comfort, and cosmetic outcomes for patients undergoing this therapy.

This extensive study encompassed 184 adult patients across 7 participating centers, bringing together diverse clinical experiences and patient demographics. The participants ranged in age from 27 to 95 years old, with a median age of 70.3 years, and included individuals with confirmed stage I or II NMSC.

Effective Treatment Methodology

The Rhenium-SCT therapy was delivered in a single session through a 50-Gy dose of rhenium-188, carefully embedded in a resin adhesive film that is applied directly to the lesion. The treatment's efficacy was measured using modified RECIST criteria during 12 months of follow-up. Quality of life was assessed at baseline, and at 6 and 12 months through the Skin Cancer Index (SCI), alongside evaluations of treatment comfort and cosmetic outcomes through patient and clinician assessments.

Impressive Results that Speak Volumes

Key findings from the study revealed impressive figures that any medical professional would consider groundbreaking:

• The overall response rate reached an astonishing 97.3%.
• A complete response was observed in 94.1% of participants.
• Only 3.2% of patients showed a partial response.
• Quality of life improved significantly, with a mean increase of 10.55 points from baseline.
• No reports of pain or discomfort during the treatment were noted.
• Patients and clinicians alike reported favorable cosmetic outcomes.
• Grade 1 hypopigmentation was the most common side effect, affecting 60.4% of the participants.
• Importantly, no treatment-emergent adverse events above Grade 2 were observed at the 12-month mark.

These remarkable results reinforce the significant advantages of Rhenium-SCT as a minimally invasive treatment option, supporting sustained efficacy, improved patient quality of life, and positive cosmetic results.

Expert Insights into the Findings

Dr. Gerhard Dahlhoff, Medical Director at OncoBeta, emphasized the substantial findings by stating, "Rhenium-SCT has consistently demonstrated effectiveness and safety in prior studies. This 12-month interim data further reinforces its value as a non-invasive, targeted treatment option for NMSC, particularly for patients seeking alternatives to surgery due to cosmetic or health-related concerns."

Shannon D. Brown III, Chief Commercial Officer and Managing Director of Europe at OncoBeta, added, "The 12-month results from the EPIC-Skin Study represent a major milestone for OncoBeta. These results support the efficacy, safety, and patient satisfaction associated with Rhenium-SCT. The patient experience in achieving positive clinical outcomes underscores the importance of our patient-first vision."

About Rhenium-SCT Therapy

Rhenium-SCT offers a unique, non-invasive solution for patients diagnosed with non-melanoma skin cancer. By utilizing the radioisotope Rhenium-188, this therapy provides targeted treatment to problem areas while sparing surrounding healthy tissue, ensuring minimal damage and swift recovery. The method avoids direct skin contact, leading to a virtually painless experience for the patient.

Discovering More About OncoBeta

OncoBeta, headquartered in Garching near Munich, Germany, has long been committed to the innovation and commercialization of advanced therapies for skin cancer treatment, particularly focusing on Rhenium-SCT. The company adheres to the highest health and safety standards while perfecting its customized application system, ensuring effective patient care.

Frequently Asked Questions

1. What is Rhenium-SCT therapy?

Rhenium-SCT is an innovative, non-invasive treatment for non-melanoma skin cancer that utilizes the radioisotope Rhenium-188 to target affected areas without harming healthy tissue.

2. What were the major findings of the EPIC-Skin Study?

The study reported an overall response rate of 97.3% with high levels of patient satisfaction and minimal side effects.

3. How does Rhenium-SCT compare to traditional treatment options?

Rhenium-SCT provides a less invasive alternative to surgery while ensuring effective results and reducing recovery times.

4. Is Rhenium-SCT suitable for all patients with non-melanoma skin cancer?

While Rhenium-SCT has shown great effectiveness, suitability depends on various factors, including cancer stage and patient health.

5. How can patients find more information about OncoBeta and Rhenium-SCT?

Patients can learn more about Rhenium-SCT and OncoBeta's offerings through their official website and by consulting with their healthcare providers.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.